In the future, we seek to obtain this data, re-estimate the efficacy and decay of anti-PD-1 (γ1,d1) and CCR2 antagonist (γ2,d2) in glioblastoma, and predict accurate doses and frequencies. Here, CCR2 is linked to glioblastoma.